Holkova, Beata <br/><br/>
A Phase II Trial of AZD6244 (Selumetinib, ARRY-142886), an Oral MEK1/2 Inhibitor, in Relapsed/Refractory Multiple Myeloma.  [electronic resource] 

 -  Clinical cancer research : an official journal of the American Association for Cancer Research  Mar 2016 
 - 1067-75 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase II; Journal Article; Research Support, N.I.H., Extramural; Research Support, N.I.H., Intramural; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1557-3265 
<br/><br/><label>Standard No.: </label>10.1158/1078-0432.CCR-15-1076  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Aged, 80 and over<br/>Benzimidazoles--administration & dosage<br/>Disease-Free Survival<br/>Female<br/>Humans<br/>Kaplan-Meier Estimate<br/>MAP Kinase Kinase Kinases--antagonists & inhibitors<br/>Male<br/>Middle Aged<br/>Multiple Myeloma--drug therapy<br/>Neoplasm Recurrence, Local--drug therapy<br/>Proto-Oncogene Proteins p21(ras)--genetics